



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Earning potential in paediatric-onset IBD – a complex interplay

Citation for published version:

Henderson, P 2022, 'Earning potential in paediatric-onset IBD – a complex interplay', *Alimentary Pharmacology and Therapeutics*, vol. 56, no. 6, pp. 1084-1085. <https://doi.org/10.1111/apt.17169>

Digital Object Identifier (DOI):

[10.1111/apt.17169](https://doi.org/10.1111/apt.17169)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Alimentary Pharmacology and Therapeutics

Publisher Rights Statement:

Author's peer reviewed manuscript as accepted for publication.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1
2
3 **Title:** Earning potential in paediatric-onset IBD – a complex interplay

4
5 **Running Head:** Earning potential in PIBD

6
7
8 **Author:** Dr Paul Henderson, MBChB, MRCPCH, Ph.D

9
10
11 **Affiliations:**

- 12
13 1. Child Life and Health, University of Edinburgh, Edinburgh, UK
14
15 2. Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for
16
17 Children and Young People, Edinburgh, UK
18
19

20
21 **Corresponding Author:**

22 Dr Paul Henderson
23
24 Consultant Paediatric Gastroenterologist
25
26 Royal Hospital for Children and Young People
27
28 50 Little France Crescent
29
30 Edinburgh
31
32 United Kingdom
33
34 Email: paul.henderson@nhslothian.scot.nhs.uk
35
36 Phone: +0044 7799 003015

37
38 **Funding:** None

39
40 **Acknowledgements:** None

41
42 **Conflicts of interest:** None
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Individuals with childhood-onset inflammatory bowel disease (IBD) have consistently
4 been shown to have similar educational attainment as the general population, albeit
5 that previous studies have been small or cross-sectional in nature.^{1,2} Conversely,
6 those with adult-onset IBD have been shown to have poor work-related outcomes,
7 likely due to the complex interactions between IBD symptoms, medical and psychiatric
8 co-morbidities and potentially income itself.^{3,4} In patients diagnosed in early adulthood,
9 reduced ability to work has been associated with lower educational attainment and
10 female sex, with disease duration and the need for biologicals or immunomodulators
11 also shown to be factors.⁵ Current data would therefore suggest that life-long earnings
12 in those with IBD are likely influenced by numerous compounding factors which
13 interact during adolescence and early adulthood.

14
15 In this issue of Alimentary Pharmacology & Therapeutics Malmberg *et al* ([reference](#))
16 use a large national case-control study to evaluate adult earnings in patients
17 diagnosed with IBD in childhood. After identifying 5,404 IBD patients diagnosed
18 <18yrs from their Swedish National Patient Register they case-matched 10:1 from the
19 general population. Analysing data from the 1990s (to include patients exposed to
20 immunomodulators) the authors analysed earnings between the ages of 20-30yrs. The
21 primary outcome was annual taxable earnings with secondary outcome annual
22 personalised disposable income. Subgroup analyses were performed stratifying for
23 sex, IBD subtype and more severe disease phenotype (i.e. those patients requiring
24 IBD surgery or long-term inpatient treatment).

25
26 Results showed that individuals with and without IBD had similar education levels
27 (except for those with more severe phenotype who had lower educational attainment),
28 marital status and unemployment. However, an increased proportion of patients with
29 IBD had a disability pension or were on sick leave compared to the general population.
30 With regard to primary outcome those with childhood-onset IBD had a modest 5.4%
31 lower annual taxable income (95%CI -9.1 to -1.8%); in those with a more severe
32 phenotype this difference was more pronounced (-16.3%; 95%CI -24.7 to -7.9%).
33 Various potential reasons for these findings were provided by the authors, such as
34 overall reduced school attendance, fatigue and loss of career drive due to chronic
35 illness. The earning gap also seemed to widen with increasing age. Interestingly there
36 was no significant difference in annual *disposable* income in those with and without
37 IBD; the authors suggest that this was likely due to the well-resourced and
38 comprehensive social security system in Sweden coupled with good job security.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Although some economies may be able to adequately support patients with chronic
4 health issues to sustain a modest income level, those living with IBD continue to have
5 a number of ongoing challenges in the workplace. These include fatigue, diarrhoea,
6 faecal incontinence, inflexible work environment and difficulty accessing appropriate
7 disability rights.⁶ It is notable that the IBD disability index developed by expert
8 consensus included indices relating to education, work and employment and social
9 security services.⁷ Although further data is required to ascertain the impact of
10 childhood-onset IBD on future employment and earnings in different economic settings
11 it is also vital that employers recognise the effect of IBD on their employees and
12 provide suitable support on a practical level.⁸
13
14
15
16
17
18
19
20
21

22 References

- 23 1. Calsbeek H, Rijken M, Dekker J, van Berge Henegouwen GP. Disease characteristics as
24 determinants of the labour market position of adolescents and young adults with chronic digestive
25 disorders. *Eur J Gastroenterol Hepatol*. 2006;18(2):203-9.
26
27
- 28 2. El-Matary W, Dufault B, Moroz SP, Schellenberg J, Bernstein CN. Education, Employment,
29 Income, and Marital Status Among Adults Diagnosed With Inflammatory Bowel Diseases During
30 Childhood or Adolescence. *Clin Gastroenterol Hepatol*. 2017;15(4):518-24.
31
32
- 33 3. Su S, Marrie RA, Bernstein CN. Factors Associated With Social Participation in Persons Living
34 With Inflammatory Bowel Disease. *J Can Assoc Gastroenterol*. 2022;5(2):59-67.
35
36
- 37 4. Bernstein CN, Kraut A, Blanchard JF, Rawsthorne P, Yu N, Walld R. The relationship between
38 inflammatory bowel disease and socioeconomic variables. *Am J Gastroenterol*. 2001;96(7):2117-25.
39
40
- 41 5. Mariappan L, Jiang XY, Jackson J, Drew Y. Emerging treatment options for ovarian cancer:
42 focus on rucaparib. *Int J Womens Health*. 2017;9:913-24.
43
44
- 45 6. Le Berre C, Peyrin-Biroulet L, Buisson A, Olympie A, Ravel MH, Bienenfeld C, et al. Impact of
46 inflammatory bowel diseases on working life: A French nationwide survey. *Dig Liver Dis*.
47 2019;51(7):961-6.
48
49
- 50 7. Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, et al. Development of
51 the first disability index for inflammatory bowel disease based on the international classification of
52 functioning, disability and health. *Gut*. 2012;61(2):241-7.
53
54
- 55 8. Paulides E, Daker C, Frampton C, Geary RB, Eglinton T, de Boer NKH, et al. Overcoming
56 Workplace Disability in IBD Patients: An Observational Study. *Inflamm Intest Dis*. 2020;5(2):84-92.
57
58
59
60